Literature DB >> 16819979

Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures.

Soon S Park1, Daewoo Lee.   

Abstract

A key pathological feature of Parkinson's disease (PD) is the selective loss of dopaminergic neurons accompanied by the formation of Lewy bodies (LB). Given the complex nature of the disease, it is imperative to develop a model system suitable for molecular and cellular manipulation in order to study the mechanisms underlying the pathogenesis of PD. Here, we report that a new in vitro model of PD has been developed by using Drosophila melanogaster primary neuronal cultures expressing a human mutant alpha-synuclein (alpha-Syn; A30P). The selective loss of dopaminergic (DA) neurons was observed when alpha-Syn was pan-neuronally expressed while non-dopaminergic neurons (e.g. GABAergic) were not influenced. This degeneration was also observed even when alpha-Syn was specifically expressed in DA neurons, demonstrating alpha-Syn toxicity is DA cell-autonomous. In all experiments, cultures 5 days or older showed clear degeneration of DA neurons whereas this degeneration was not significant in 3-day-old cultures. In addition, there were intracellular aggregations in 5-day or older alpha-Syn neurons that were recognized by anti-alpha-Syn or ubiquitin antibodies, demonstrating the formation of LB-like inclusions. By contrast, no such aggregations were found in 3-day-old neurons. The results demonstrate that mutated human alpha-Syn expressed in Drosophila primary neuronal cultures causes the selective loss of DA neurons and the formation of cellular aggregations. Therefore, this is one of the first in vitro models recapitulating two important cellular features of PD and will be useful in examining mechanisms underlying selective neurodegeneration mediated by alpha-Syn.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16819979     DOI: 10.1111/j.1460-9568.2006.04844.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  8 in total

Review 1.  Nutrient-driven O-GlcNAc in proteostasis and neurodegeneration.

Authors:  Ilhan Akan; Stephanie Olivier-Van Stichelen; Michelle R Bond; John A Hanover
Journal:  J Neurochem       Date:  2017-11-20       Impact factor: 5.372

2.  The impact of genetic research on our understanding of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

3.  Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism.

Authors:  Kien Trinh; Laurie Andrews; James Krause; Tyler Hanak; Daewoo Lee; Michael Gelb; Leo Pallanck
Journal:  J Neurosci       Date:  2010-04-21       Impact factor: 6.167

4.  Suppression of inhibitory GABAergic transmission by cAMP signaling pathway: alterations in learning and memory mutants.

Authors:  Archan Ganguly; Daewoo Lee
Journal:  Eur J Neurosci       Date:  2013-02-07       Impact factor: 3.386

5.  Selective degeneration of dopaminergic neurons by MPP(+) and its rescue by D2 autoreceptors in Drosophila primary culture.

Authors:  Lyle Wiemerslage; Bradley J Schultz; Archan Ganguly; Daewoo Lee
Journal:  J Neurochem       Date:  2013-03-24       Impact factor: 5.372

6.  Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans.

Authors:  Pengxiu Cao; Yiyuan Yuan; Elizabeth A Pehek; Alex R Moise; Ying Huang; Krzysztof Palczewski; Zhaoyang Feng
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

7.  alpha-Synuclein and neuronal cell death.

Authors:  Mark R Cookson
Journal:  Mol Neurodegener       Date:  2009-02-04       Impact factor: 14.195

8.  Identification of neural outgrowth genes using genome-wide RNAi.

Authors:  Katharine J Sepp; Pengyu Hong; Sofia B Lizarraga; Judy S Liu; Luis A Mejia; Christopher A Walsh; Norbert Perrimon
Journal:  PLoS Genet       Date:  2008-07-04       Impact factor: 5.917

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.